Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HeartBeamBEAT -2.26%26 12-1 Month Momentum % is -61.21% as of Sep. 09, 2026. GuruFocus rates BEAT with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 655 Healthcare Providers & Services companies, HeartBeam ranks worse than 90.53% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-09), HeartBeam's 12-1 Month Momentum % is -61.21%.
The industry rank for HeartBeam's 12-1 Month Momentum % or its related term are showing as below:
BEAT's 12-1 Month Momentum % is ranked worse than 90.53% of 655
companies
in the Healthcare Providers & Services industry
Industry Median: -11.96
vs BEAT: -61.21
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
HeartBeam 12-1 Month Momentum % Related Terms
BEAT vs CRVW, ONMD, HCTI: 12-1 Month Momentum % Comparison
For the Health Information Services subindustry, HeartBeam's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeartBeam 12-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HeartBeam's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where HeartBeam's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -61.21% mean?
HeartBeam (BEAT) has a 12-1 Month Momentum % of -61.21% as of Sep. 09, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on HeartBeam and its competitors. According to the industry distribution chart, HeartBeam ranks #593 out of 655 companies in the Healthcare Providers & Services industry, placing it in the top 90.5%.
Is HeartBeam's 12-1 Month Momentum % too high?
HeartBeam's current 12-1 Month Momentum % is -61.21%. Based on the distribution chart, HeartBeam ranks #593 out of 655 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, HeartBeam has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does HeartBeam's 12-1 Month Momentum % compare to CRVW and ONMD?
According to the Healthcare Providers & Services industry distribution chart, HeartBeam ranks #593 out of 655 companies for 12-1 Month Momentum %. This places HeartBeam in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Healthcare Providers & Services company?
A good 12-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on HeartBeam and its competitors. HeartBeam's current 12-1 Month Momentum % is -61.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartBeam stock overvalued right now?
HeartBeam (BEAT) has a current 12-1 Month Momentum % of -61.21%. The current 12-1 Month Momentum % is -61.21%. HeartBeam's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For HeartBeam (BEAT), the current 12-1 Month Momentum % is -61.21% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
26GF Score
Get the complete analysis for BEAT
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEAT has been successfully added to your 
